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Expression of surface NKG2D ligand MIC on tumor cells is deemed to stimulate NK and co-stimulate CD8 T cell
anti-tumor immunity. Human cancer cells however frequently adopt a proteinase-mediated shedding strategy
to generate soluble MIC (sMIC) to circumvent host immunity. High levels of sMIC have been shown to correlate
with advanced disease stages in cancer patients. The underlying mechanism is currently understood as systemic
downregulation of NKG2D expression on CD8 T and NK cells and perturbing NK cell periphery maintenance.
Herein we report a novel mechanism by which sMIC poses immune suppressive effect on host immunity and
tumor microenvironment. We demonstrate that sMIC facilitates expansion of myeloid-derived suppressor cells
(MDSCs) and skews macrophages to the more immune suppressive alternative phenotype through activation of
STAT3. These findings further endorse that sMIC is an important therapeutic target for cancer immunotherapy.
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Expression of surface NKG2D ligands on tumor cells is
well proven to provoke tumor rejection through activa-
tion of NK and CD8 T cells in experimental animal
models [1-3]. Human cancers however broadly evade
this mechanism by adopting a protease-dependent shed-
ding mechanism to generate soluble NKG2D ligands
[4-6]. Among the many identified human NKG2D li-
gands [7], the MHC I chain-related molecule (MIC) is
the best described and characterized ligands in human
cancer. Elevated shedding of cell surface MIC has been
associated with advanced disease stages and metastasis
in many types of epithelial cancers [4,7-10]. It is well ac-
cepted that tumor-derived soluble MIC (sMIC) is a
negative immune regulator in cancer patients, although
the underlying mechanisms are not fully understood.
Multiple mechanisms have been uncovered by which
soluble sMIC insults the immune system. Tumor-
derived sMIC has been shown broadly downregulating* Correspondence: wujjd@musc.edu
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and thus impair their effector function [4,10-12]. Very
recently, we further show that tumor-derived sMIC per-
turbs NK cell periphery homoeostatic maintenance
through disrupting the ability of NK cell to self-renew
[13]. In this study, we report a novel mechanism by
which tumor-derived sMIC negatively regulates host im-
munity and the immune reactive tumor microenviron-
ment. With complementary in vivo and in vitro assays,
we demonstrate that sMIC facilitates expansion of
myeloid-derived suppressor cells (MDSCs) and skews
macrophages to the alternative immune suppressive
phenotype through activation of STAT3.Results and discussion
sMICB increases frequency of MDSC and arginase I+ cells
in bi-transgenic TRAMP/MIC mice
MIC is not expressed in rodents, which limits the poten-
tial to study the global impact of tumor-derived sMIC
on host anti-tumor immunity in vivo. To overcome this
limitation and to take the advantage that human MICB
can serve as a mouse NKG2D ligand and activate mouse
NKG2D [2,13-15], we have recently generated a bi-
transgenic TRAMP/MICB spontaneous prostate tumoris is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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specifically expressed in the autochthonous transgenic
adenocarcinoma mouse prostate (TRAMP) under the
prostate-specific promoter [13]. The TRAMP/MICB
model highly resembles human cancer patients in the
kinetics of oncogenesis and tumor immunity in that
MIC expression is concurrent with oncogenic events and
MIC shedding correlates with tumor progression [13].
In comparative studies of TRAMP/MICB mice with
TRAMP littermates, we found that 1) TRAMP/MICB
mice had significantly higher numbers of MDSC in the
spleen and tumor infiltrates than their TRAMP litter-
mates; 2) amongst the TRAMP/MICB animals, those
with high levels of serum sMICB had significantly higher
numbers of MDSC, a population generally defined as
CD11b+GR-1+, in the spleen and tumor infiltrates
(Figure 1a, b). We also found that significantly ele-
vated number of cells that are arginase I+ in the
TRAMP/MIC tumor infiltrates than in the TRAMP
counterparts (Figure 1c, d). Moreover, among tumors
from TRAMP/MICB mice, those with poorly differenti-
ated (PD) tumors had significantly higher numbers of
MDSC and arginase I+ cells in the tumor infiltrates than
those with well-differentiated (WD) tumors (Figure 1a, d).
Of note, the PD tumors are pathologically defined as inva-
sive tumors with large mass [13,16,17]; whereas the WD
tumors are pathologically organ-confined tumor with
small mass [13,16,17] (Additional file 1: Figure S1). Not-
ably, TRAMP/MIC mice with PD tumors also have signifi-
cantly higher levels of serum sMIC than those with WD
tumors (Figure 1e). Moreover, in TRAMP/MICB mice,
the number of MDSCs in the spleen and tumor infiltrates
significantly correlated with serum levels of sMIC
(Figure 1f, g). Furthermore, neutralization of serum sMIC
with a monoclonal antibody resulted in significant reduc-
tion of MDSCs in the spleen and TILs (Additional file 2:
Figure S2). Given that arginase I is an emerging immune
suppressive metabolic enzyme produced by MDSC and
alternatively activated macrophages [18], these observa-
tions prompted us to investigate whether sMIC plays a
role in the generation or expansion of MDSC and alter-
native macrophages.
Intraperitoneal injection of sMIC promotes local
accumulation of MDSCs and macrophages with
alternative phenotype
MDSCs are a collective of heterogeneous population of
immature myeloid cells (IMC) that are endowed with a
robust immunosuppressive activity through secretion of
immune suppressive factors, such as inducible nitric
oxide synthase (iNOS), arginase, and indoleamine 2,3-
dioxygnases (IDOs) [19]. The heterogeneous MDSC
population are generally defined by surface marker
CD11b+GR-1+ and considered to be immune suppressivein tumor host. MDSCs can be expanded during cancer
development due to blockage of normal myeloid cell dif-
ferentiation and maturation by tumor or tumor stroma-
derived intrinsic factors [19].
To provide evidence that sMIC contributes in part to
the accumulation of MDSC in the TRAMP/MICB mice,
we purified soluble MICB (sMICB) from 293 F-sMICB
cell culture supernatant and intraperitoneally injected
the sMICB into B6 or BALB/c mice (200 μg/mouse). As
early as day three post-injection, a significantly higher
numbers of cells with MDSC phenotype Gr-1+CD11b+
were found in the peritoneal fluid in mice that received
sMICB injection than those having received control ve-
hicle injection (Figure 2a). By day 6 post-sMIC injection,
in addition to the significant increase in the number of
cells expressing the MDSC phenotype (CD11b+Gr-1+),
the number of cells that express markers for the alterna-
tive macrophage, F4/80+CD11clow/−CD206+ arginase I+,
was also significantly increased in the PEC from mice that
received sMICB injection in comparison to those having
received control vehicle injection (Figure 2b, c; data not
shown). A small percentage of F4/80+CD11c+CD206− cells
that would be considered as type I macrophage were also
increased in association with sMICB injection, however
not at a significant level (Figure 2b; data not shown).
Notably, no significant amount of anti-MIC antibody
was detected in the serum or peritoneal fluid at the
given experimental time points nor were activation
markers of lymphocyte subsets detected locally or sys-
tematically (data not shown). To further support that
the in vivo effect is not due to unknown immune mod-
ulators resulted from sMICB purification process, we
performed similar experiments with serum-free culture
media, serum-free conditioned media from TRAMP-C2
cells bearing expression vector control, and serum-free
conditioned media from TRAMP-C2 cells expressing
sMICB. We obtained consistent results as with purified
sMICB (Additional file 3: Figure S3). These data dem-
onstrate that sMIC can facilitate the accumulation of
CD11b+Gr-1+ cells and macrophages with alternative
F4/80+CD206+ arginase I+ phenotype independent of
tumor-derived intrinsic factors.
sMICB promotes induction of MDSC in vitro through
NKG2D and activation of STAT3
We addressed whether the accumulation of MDSC in-
duced by sMIC in vivo is a direct effect or an act
through extrinsic cell mediators. We first co-cultured
bone marrow cells isolated from wild type B6 or BALB/c
mice with the mouse prostate tumor cell line TRAMP-
C2 cells engineered to express sMICB (TC2-sMICB)
or control TRAMP-C2 (TC2) cells that contain the ex-
pression vector only at various ratios in the presence of
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Figure 1 Increased MDSC and arginase I+ cell population in the peripheral and tumor parenchyma in TRAMP/MIC mice is associated
with elevated serum sMIC. (a) Representative plot of flow cytometry analysis demonstrating the population of MDSC (CD11b+GR-1+) in the
spleen and tumor parenchyma in TRAMP/MIC (MIC+) and TRAMP (MIC−) tumor-bearing TRAMP mice. (b) Summary data of MDSC percentage in
splenocytes and tumor infiltrates. (c) Representative micrograph showing arginase I+ cells in the parenchyma of TRAMP/MIC and TRAMP tumors.
(d) Summary data of arginase I+ cells in TRAMP/MIC and TRAMP tumors. (e) Serum levels of sMIC in TRAMP/MIC mice. (f, g) Correlation of serum
levels of sMIC with numbers of MDSC in the splenocytes (f) and CD45+ tumor infiltrates (g) of TRAMP/MIC mice. A minimum of 10 TRAMP/MICB
and TRAMP mice was analyzed. WD, well-differentiated. PD, poorly-differentiated.
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After 3 days of co-culture, the number of CD11b+ Gr-1+
cells in the culture with PBS remained at a similar
level to what was found in normal bone marrow con-
tains [19] (20% to 30%, Figure 3a). When co-cultured
with TC2 tumor cells, the number of CD11b+ Gr-1+
cells were significantly increased (46% ± 3.8%), consist-
ent with current understanding that tumors can pro-
mote MDSC accumulation [19,21]. When co-cultured
with TC2-sMICB cells, a further significant increase in the
number of CD11b+ Gr-1+ cells was evident (70% ± 5.2%,
Figure 3a). These observations suggest that sMICB mayFigure 2 Injection of sMICB promotes accumulation of MDSC and Arg
cytometry plots and summary data demonstrating the percentage of CD11
B6 (n = 6) or BALB/c (n = 5) mice 3 days post i.p. injection with 200 μg sMIC
demonstrating expression of macrophage subtype marker CD206 (type II) a
(c) Representative flow cytometry plots and summary data demonstrating
independent experiments. *P < 0.05. **P < 0.01.directly facilitate MDSC accumulation during myeloid cell
differentiation.
We next addressed whether sMIC can induce MDSC
accumulation in vitro in the absence of tumor cells. We
cultured bone marrow cells with various concentrations
of purified sMICB in the presence of GM-CSF and ana-
lyzed the cells at day 3 of culture. As representatively
shown in Figure 3b, sMIC elicited a dose-dependent ef-
fect on the induction of Gr-1+CD11b+ cells. NKG2D, the
only known cell surface receptor for sMIC, was detected
on the surface MDSCs, with a trend of increased expres-
sion after exposure to GM-CSF (Figure 3c). We thusinase I+ macrophage in the peritoneal. (a) Representative flow
b+Gr-1+ population in peritoneal exudate cells (PECs) harvested from
B. (b) Representative flow cytometry plots and summary data
nd CD11c (type I) on gated F4/80+ PECs 6 days post sMICB injection.
arginase I expression in F4/80+CD206+ PECs. Data represent four
Figure 3 sMIC promotes induction of MDSC through engagement of NKG2D and activation of STAT3. (a) Bone marrow cells from B6
mice were co-cultured with sMICB expressing prostate tumor cell line TRAMP-C2 (TC2-sMICB-GFP, also as TC2-sMICB) or control TC2-GFP cells at a
ratio of 10:1 for 3 days. Cells were harvested and stained with antibodies specific to CD45 (to differentiate myeloid cells from tumor cells), Gr-1,
and CD11b for flow cytometry analyses. Data show representative plots and summary of CD11b+Gr-1+ in gated CD45+ cells. (b) Bone marrow cells
from B6 mice were cultured in the presence of GM-CSF, with various concentration of purified sMICB for 3 days. Cells were harvested and analyzed for
CD11b and Gr-1 expression. Data show representative plots and summary of the percentage of cells that are CD11b+Gr-1+. (c) Representative
histogram showing NKG2D expression on myeloid cells with various culture conditions. Grey-filled profile, staining with isotype control. Open
profile, staining with anti-NKG2D antibody CX5. (d) Bone marrow cells from B6 mice were cultured with GM-CSF in the presence or absence
of sMICB (25 ng/ml) and with and without the NKG2D blocking antibody CX5 or STAT3 inhibitor AG490. Data show representative plots and
summary of CD11b+Gr-1+ cells after 3 days of culture. (e) Levels of intracellular phosphorylated STAT3 in bone marrow myeloid cells cultured in the
condition as described in (d). Three replicates were performed in each experiment. Data represent five independent experiments. *P < 0.05.
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of sMIC in the current experimental setting. In the pres-
ence of the NKG2D blocking antibody CX5, sMIC failed
to augment MDSC expansion (Figure 3d). This observa-
tion was substantiated by experiments demonstrating
that sMIC has no effect on bone marrow cells fromNKG2D−/− mice (Additional file 4: Figure S4a). To-
gether, these data confirmed a direct effect of sMIC on
the accumulation of myeloid cells with MDSC pheno-
types (Gr-1+CD11b+).
We sought to further understand the molecular path-
ways under which sMIC induces MDSC accumulation.
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that include cyclooxygenase-2(COX2), prostaglandins
[22], stem cell factor (SCF) [23], macrophage colony-
stimulating factor (M-CSF), IL-6 [24], GM-CSF [20], and
vascular endothelial growth factors [25]. Signaling path-
ways triggered by most of these factors converge to
the activation of the signal transducer and activator of
transcription 3 (STAT3) [26], which is the main tran-
scriptional factor regulating MDSC expansion [27,28].
MDSCs from tumor bearing mice showed markedly in-
creased levels of phosphorylated STAT3 (pSTAT3) com-
pared with IMCs from naïve mice [28]. As shown in
Figure 3d, addition of the STAT3 inhibitor AG490
not only mitigated the effect of sMICB on MDSC accu-
mulation but also nearly obliterated MDSC expansion
(Figure 3d). Concurrently, the intracellular levels of
pSTAT3 was decreased to base-level with anti-NKG2D
blocking antibody CX5 and abolished with pSTAT3 in-
hibitor AG490 (Figure 3e). Given that GM-CSF induce
potent STAT3 activation and that STAT3 is a key tran-
scriptional factor in regulating MDSC expansion [19,20],
the much more profound effect of AG490 than anti-
NKG2D antibody on MDSC expansion and STAT3 is
anticipated. No significant change in the levels of STAT3
phosphorylation was induced by sMICB in the same
experiment settings with bone marrow cells from
NKG2D−/− mice [17] (Additional file 4: Figure S4b).
Collectively, these data demonstrate that sMIC in-
duces MDSC expansion through activation of STAT3
pathways.
sMIC activation of STAT3 skews macrophage
differentiation into to the alternative phenotype
We have observed increased arginase I expression in the
tumor tissue from our TRAMP/MIC mice that have
high levels of circulating sMIC and also in mice that
were injected with purified sMIC. We thus sought to ask
whether prolonged sMIC exposure can skew myeloid
cells into an immune suppressive arginase I+ alternative
phenotype during differentiation. We cultured bone
marrow cells isolated from B6 mice with conditioned
media harvested from L929 cells (CM-L929) to allow
macrophage generation for 3 days [29]. With the
addition of 25 ng/ml of sMICB to the media at day 3
and allowing cells to continue differentiation for add-
itional 3 days (Figure 4a), we found that addition of
sMICB in the culture significantly increased the level of
F4/80 expression (Figure 4b). When the F4/80+ popula-
tion were further analyzed, the number of cells that ex-
press the scavenger receptor CD206, a marker for the
alternative phenotype of macrophage, was significantly
increased with inclusion of sMICB (Figure 4c). Moreover,
these CD206+ cells also express arginase I (Figure 4d),
confirming the phenotype of the alternatively activatedmacrophages. Blocking NKG2D with the antibody CX5
or inhibiting STAT3 activation with AG490 similarly di-
minished the impact of sMICB (Figure 4b, c, d), indicat-
ing that sMICB acts through NKG2D and STAT3
pathway to skew macrophage into the alternatively acti-
vated phenotype. This conclusion was confirmed by ex-
periments demonstrating that sMICB had no effect on
macrophage differentiation originated from NKG2D−/−
bone marrow cells (Additional file 4: Figure S4c). To con-
firm that the STAT3 pathway is activated by sMICB dur-
ing macrophage differentiation, we assessed levels of
intracellular pSTAT3 and showed that STAT3 was phos-
phorylated in macrophage as early as 2 h after exposure
to sMICB and the level of pSTAT3 persists with the pres-
ence of sMICB (Figure 4e). We obtained consistent re-
sults from bone marrow cells isolated from BALB/c mice
(Additional file 5: Figure S5). Given that the expression
of NKG2D is detected in activated macrophages, these
data suggest that activation of STAT3 signaling via
sMIC/NKG2D interaction can promote macrophage
polarization into a more immune suppressive alternative
phenotype. Notably, activation of STAT6 can also promote
macrophage differentiation into the alternatively activated
phenotype [30]. We observed a base level of pSTAT6 in
the macrophages with CM-L929 media; however, the level
was not influenced by sMIC (data not shown). These ob-
servations provided an explanation of the sustained per-
centage of ArgI+CD206+ cells with the STAT3 inhibitor
AG490 (Figure 4d).
To this end, we demonstrate that tumor-derived sol-
uble NKG2D ligand sMICB facilitates the expansion of
MDSC and skews macrophage differentiation into an
alternatively active phenotype through NKG2D and acti-
vation of the STAT3 pathway. Classically, activation of a
PI3K/Grb2-Vav pathway is the canonical outcome of
NKG2D signaling via coupling to the adaptor molecule
DAP10 in both mouse and human cells [31,32], although
NKG2D in mouse, ambiguously in human, has been
shown to promiscuously and selectively associate with
DAP10 or DAP12 adaptor molecule, depending on the
availability of the adaptor partners, cell types, and cell
activation status [33-36]. Whether NKG2D signaling in
MDSC or activated macrophage primarily activates the
PI3K pathway with subsequent activation of STAT3
pathways or directly activates the STAT3 pathway is an
interesting question to be further investigated. It has
been shown that PI3K signaling can bisect at phos-
phatidylinositol 3,4,5-trisphosphate (PIP3) to activate the
non-receptor bone-marrow tyrosine kinase BTK and the
downstream STAT3 signaling during cellular oncogenic
transformation [37]. Provided with this knowledge, it is
reasonable to speculate that activation of STAT3 path-
ways via NKG2D signaling in the bone marrow-
originated MDSCs and macrophages lies downstream of
Figure 4 sMICB skews macrophages into alternative activated phenotype through NKG2D and activation of STAT3. B6 mice bone
marrow cells were cultured in the presence of L929 conditioned media (CM-L929) for 3 days and cultured continually with or without sMICB in
combination with NKG2D blocking antibody CX5 or STAT3 inhibitor AG490 for additional 3 days before harvest. Cells were stained with
anti-CD206, anti-CD11c, and anti-F4/80 in combination with intracellular Arginase I staining. (a) Schema of bone marrow (BM) culture
condition. (b, c, d) Representative histogram and summary data showing that sMIC increases the expression of F4/80 (b), CD206 in gated F4/80+ cells
(c), and arginase I (arg I) in CD206+ cells (d). Data also show that blocking NKG2D or STAT3 mitigates the effect of sMICB. (e) Intracellular levels of
pSTAT3 in BM-derived macrophages at various time points post-exposure to sMICB. Three replicates were performed in each experiment.
Data represent five independent experiments. *P < 0.05.
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future investigation to test this speculation with specific
PI3K or BTK inhibitors.
Conclusion
Tumor-derived soluble NKG2D ligands, namely sMIC, is
known to negatively impact host immune response by
downregulating NKG2D expression on effector NK and
CD8 T cells and most recently shown by perturbing NK
cell peripheral maintenance. Here we demonstrate thatsMIC can also promote the expansion of MDSC and
skew macrophage into a more immune suppressive
phenotype in a given microenvironment. We demon-
strated that sMIC can activate STAT3 pathway in cells
of myeloid lineage to foster their immune suppressive
potential. We have demonstrated a novel mechanism by
which tumor-derived sMIC may temper the immune re-
active tumor microenvironment. Our findings further
emphasize the significance of targeting sMIC for cancer
immune therapy.
Xiao et al. Journal of Hematology & Oncology  (2015) 8:13 Page 8 of 10Methods
Reagents, constructs, and cell lines
STAT3 inhibitor AG490 was purchased from Invivogen
(San Diego, CA, USA). cDNA containing the α1-3 ecto-
domain of MICB fused with HIS6-Tag at the C-terminus
was synthesized by GENEWIZ Inc. (South Plainfield, NJ,
USA) and subcloned into the retroviral expression vec-
tor pBMN-GFP as described previously [14]. The sMICB
expression plasmid pBMN-GFP-sMICB or control vec-
tor pBMN-GFP was transfected into 293 T cells. After
2 weeks of selection with puromycin (5 μg/ml), GFP-
positive cells were isolated by flow cytometry sorting.
Serum-free culture supernatant of sorted GFP+ 293 T
cells was collected and subjected to Ni-sepharose
Fast Flow column from (GE Healthcare, Pewaukee,
WI, USA) and eluted with imidazole gradient increase
method according to manufacturer’s instruction. The
elution was loaded onto the Hydrophobic Interaction
Chromatography (HIC) column (GE Healthcare) for size
fractionation. The final collected fraction was buffer ex-
change with the PBS (pH 7.2). The purity of sMICB after
buffer exchange was assayed by SDS-PAGE gel and
Western-blotting with anti-MIC antibody (Additional
file 6: Figure S6). Specific binding of purified recombin-
ant sMICB to mouse NKG2D was confirmed by flow
cytometry analyses (Additional file 6: Figure S6). Gener-
ation of sMICB-expressing TRAMP-C2 cells was de-
scribed previously [14]. Tumor cell lines TRAMP-C2,
derivatives, and mouse fibroblast L929 cell line were
maintained in Dulbecco modified Eagle medium (DMEM)
plus 10% fetal bovine serum and antibiotics. Conditioned
media of L929 cells was collected, centrifuged, and filtered
through a 0.22-μm filter before being applied to bone mar-
row culture.
Mice and in vitro bone marrow differentiation
All animal procedures were approved by the MUSC
Institutional Animal Care and Use Committee. 7- to 10-
week-old male C57BL/6 and BALB/c mice were pur-
chased from The Jackson Laboratory (Bar Harbor, ME,
USA). NKG2D-deficient mice (gift of Dr. David Raulet,
University of California at Berkeley) were bred in house.
All mice were housed in Specific Pathogen Free facility.
Single cell suspension of bone marrow (BM) cells were
plated at the density of 3 × 106 cells/ml in DMEM
supplemented with 10% fetal bovine serum, 50 mM
2-mercaptoethanol, 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid buffer (Life technolo-
gies, Grand Island, NY, USA), 1 mM sodium pyruvate,
100 U/ml penicillin, 100 mg/ml streptomycin, and amino
acids (1.5 mM L-glutamine, L-arginine, and L-asparagine),
with or without 1 ng/ml rmGM-CSF (Biolegend, San
Diego, CA, USA). sMICB protein of designated concentra-
tion was added where indicated. In some experiments,bone marrow cells were cultured with conditioned media
derived from L929 cell lines.
Peritoneal cell isolation
Mice were injected via intraperitoneal (i.p) routine with
sMICB or control PBS flow through from the culture
supernatant of 293 F cells that were transduced with
control vector expressing HIS6-Tag alone. At indicated
time points, animals were euthanized and the peritoneal
exudate cells (PECs) were harvested by lavage with
10 ml of ice-cold PBS.
Flow cytometry
Cells were stained using combination of fluorochrome-
conjugated anti-mouse CD11b and Gr-1 antibody to define
the general population of MDSC and fluorochrome-
conjugated anti-mouse F4/80 in combination with CD206
and CD11c and intracellular staining of arginase I to define
the phenotype of macrophage. All fluorescence-conjugated
antibodies were from eBioscience except for rabbit anti-
pSTAT3 (Cell signaling, Danvers, MA, USA). Appropri-
ately conjugated species and isotype-matched IgG was
used as staining controls. Multi-colored flow cytometry
data were collected on a BD LSRII flow cytometer and ana-
lyzed with FlowJo software (Tree Star).
Statistical analysis
All results are expressed as the mean ± SEM. Differences
between the mean of groups were analyzed using stu-
dent’s t-test. P < 0.05 was considered as significant.
Additional files
Additional file 1: Figure S1. Prostate weight in TRAMP and TRAMP/MICB
animals. This data has been published partially (references 13, 16, 17). The
poorly-differentiated (PD) and well-differentiated (WD) tumors were defined
according to pathology criteria. Generally, PD tumors are invasive tumors.
Additional file 2: Figure S2. Representative flow cytometry plots
demonstrating that neutralizing circulating sMIC with a monoclonal
antibody reduces the population of MDSC in the spleen and tumor
infiltrates (TILs). Data represents at least five animals in the control or
anti-sMIC treated group.
Additional file 3: Figure S3. Conditioned culture medium (CM) from
TRAMP-C2-sMICB (TC2-sMICB) cells induce expansion of MDSC in vivo. B6
mice were injected i.p. with 200 μl of control serum-free culture media,
conditioned media collected from TRAMP-C2 mouse prostate tumor cells
with expression vector control (TC2-Vector) or conditioned media
collected from TC2-sMICB cells at day 1 and day 3. Mice were sacrificed at
day 6. PEC were collected and analyzed for the MDSC. Data represent five
animals in each experiment. The experiments were repeated three times
and consistent results were obtained.
Additional file 4: Figure S4. sMICB has no effect on NKG2D-deficient
myeloid MDSC expansion or macrophage polarization. Bone marrow (BM)
cells from wild-type or NKG2D−/− B6 mice were cultured in MDSC/
macrophage differentiation media (L929-CM) supplemented with control
flow-through from 293 T supernatant or purified sMICB (50 ng/ml). At day
3 of culture, cells were analyzed for MDSC population and STAT3
phosphorylation in MDSC (a, b). At day 6 of culture, cells were analyzed for
Xiao et al. Journal of Hematology & Oncology  (2015) 8:13 Page 9 of 10macrophage (gated on F4/80+) phenotypes (c, d). Data represents three
independent experiments with three replicates in each experiment.
Additional file 5: Figure S5. sMICB skews macrophages into alternative
phenotype through NKG2D and activation of STAT3 in BALB/c background.
Bone marrow cells from BALB/c mice were cultured in the presence of L929
conditioned media (CM-L929) for 3 days and cultured continually with or
without sMICB in combination with NKG2D blocking antibody CX5 or STAT3
inhibitor AG490 for additional 3 days before harvest. Cells were stained with
anti-CD206, anti-CD11c, and anti-F4/80 in combination with intracellular
arginase I staining. (a, b) Representative histogram and summary data
showing that sMIC increases the expression of CD206 in gated F4/80+
cells (a), and arginase I (Arg I) in gated CD206+ cells (b). Data also show
that blocking NKG2D or STAT3 mitigates the effect of sMICB. Data represent
five independent experiments. *P< 0.05.
Additional file 6: Figure S6. Validation of purified sMICB. (a) Coomassie
blue staining of SDS gel of sMICB elution after PBS buffer exchange.
(b) Western-blot probed with anti-MIC antibody H-300 (Santa Cruz)
and HRP-conjugated donkey anti-rabbit secondary antibody. Bioactive
sMIC produced in mammalian system is highly glycosylated. Lane 1,
without PNGaseF de-glycosylation. Lane 2, after PNGaseF de-glycosylation.
(c) Histogram of flow cytometry showing specific binding of purified sMICB
to mouse NKG2D on mouse NK1.1 (mNK1.1) and MDSC (mMDSC).
Mouse (B6) splenic NK cells or bone marrow-derived MDSCs were stained
with purified sMICB (HIS-Tagged) (20 μg/ml) followed by rabbit anti-HIS
antibody and PE-conjugated goat anti-rabbit antibody. Dark grey profile
represents sMICB binding. Black profile represents reduced sMICB binding
when cells were pre-incubated with NKG2D blocking antibody CX5
(10 μg/ml). Light grey profile represents control rabbit IgG staining.
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